EGFR and cancer: In this work, we focused on antisense oligonucleotides decorated with boron clusters (FESAN), known as B-ASOs, which have dual therapeutic potential against cancer cells—they may act as inhibitors of EGFR gene expression and boron carriers for BNCT.